Johnson & Johnson at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Chris Schott - JP Morgan - Analyst : Right. About a year ago you put out a annual top line growth target of 5% to 7% 2025 through 2030 for the total company. What is your comfort today with hitting that target? And what do you see as the key drivers of getting to that type of growth rate?

Question: Chris Schott - JP Morgan - Analyst : Great. Maybe turning to the big news of the day, the acquisition of ITCI. [Would you just help] highlight a little bit more on what brought you to that asset and how you see Caplyta fitting into the broader J&J portfolio?

Question: Chris Schott - JP Morgan - Analyst : Right. All sounds great for the long term. One of the nearer term questions we get I think is around the 3% growth target for J&J for 2025. Can you just go through some of the pushes and pulls that give you confidence in that target for -- as we think about this?

Question: Chris Schott - JP Morgan - Analyst : But the underlying kind of operational piece, you're feeling very --? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 5:00PM, JNJ.N - Johnson & Johnson at JPMorgan Healthcare Conference

Question: Chris Schott - JP Morgan - Analyst : Maybe just pivoting a little bit to some of the administration dynamics. Just first of all, you went through the initial IRA price negotiation discussions last year as a company. Maybe just what are some of your main takeaways from that process and kind of where J&J ended up with those discussions?

Question: Chris Schott - JP Morgan - Analyst : What was the one you had the -- you had XARELTO in there too.

Question: Chris Schott - JP Morgan - Analyst : And just with the new administration coming in this year, just how are you thinking about the potential for change within the healthcare regulatory environment? I guess, what's top of mind for you?

Question: Chris Schott - JP Morgan - Analyst : Maybe pivoting to the pharma business. No more detail. Just immunology first. STELARA is facing biosimilars this year, it's one of your largest products. Latest on erosion curve and how we should think about analogies to think about as STELARA starts to see competition. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 5:00PM, JNJ.N - Johnson & Johnson at JPMorgan Healthcare Conference

Question: Chris Schott - JP Morgan - Analyst : Just one thought there. Just as I think about the IL-23 market, TREMFYA versus the oral IL-23, how do you see those two playing off against each other?

Question: Chris Schott - JP Morgan - Analyst : Right. Maybe looking at one of your big franchises, myeloma seems like one of these end-to-end opportunities that you were talking about earlier. Just talk about the prospects for growth when you think about the portfolio of assets the companies put together.

Question: Chris Schott - JP Morgan - Analyst : Right. Maybe one last one on the pharma side. You also have a broad portfolio of assets and pipeline. Where do you see the most significant disconnects between J&J's internal view and how The Street is thinking about the pharma business?

Question: Chris Schott - JP Morgan - Analyst : Maybe pivoting over to MedTech. I know improving the growth prospects and kind of positioning this franchise was one of your key priorities during your tenure as CEO. A few years into this process, we'd just like to get your sense of where we are in that process? Kind of like what inning in the -- of repositioning do you feel J&J is at this point?

Question: Chris Schott - JP Morgan - Analyst : Maybe just one quick comment on VARIPULSE some of the recent news. What should we be watching there? And what are the next steps to think about?

Question: Chris Schott - JP Morgan - Analyst : Great. Maybe in the last couple of minutes here. Obviously, we're coming off a big announcement of a deal today, but just the latest priorities for J&J as we think both MedTech and pharma from here. What should we be thinking about in terms of priorities for you as you think about kind of further expanding the portfolio via BD? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 5:00PM, JNJ.N - Johnson & Johnson at JPMorgan Healthcare Conference

Question: Chris Schott - JP Morgan - Analyst : Excellent. Well, I think we're just out of time. Joaquin, thanks so much for joining us. Really appreciate the comments today.